We are delighted to announce that PrecisionLife has been named Winner – Best Tech Innovation to Promote Health at the 2025 Tech Impact Awards, on 2 December during London Tech Week.
This recognition honors our team’s dedication and our groundbreaking AI-led combinatorial analytics platform, which is already transforming how complex chronic diseases are predicted, treated, and prevented worldwide.
This award comes at an especially significant time for PrecisionLife. This week we published our landmark study of Myalgic Encephalomyelitis (ME), the most detailed genetic analysis ever conducted in the disease – identifying over 250 core genes linked to ME, uncovering shared biology with long COVID, and revealing dozens of promising opportunities for drug repurposing supported by genetic biomarker tests, offering potential for faster and lower-risk routes to developing targeted treatments.
Our AI-powered combinatorial analytics platform transforms patient data into clinically actionable insights – offering hope for better care, faster diagnosis, and ultimately, new paths to treatment.
The Best Tech Innovation to Promote Health category recognizes organizations whose technology has a tangible, positive impact on health.
For us, the Award is a strong endorsement of our mission to drive precision medicine beyond rare diseases and cancer. Chronic diseases like ME, ALS, endometriosis, diabetes, Alzheimer's, and other complex conditions account for the majority of global healthcare burdens. By leveraging our platform to decode complex disease biology rather than treating symptoms in isolation, we are enabling predictive, preventive, and personalized care at scale.
We thank the Tech Impact Awards judges, our scientific and patient collaborators, and everyone on the PrecisionLife team. Together, we are one step closer to a future where chronic disease can be understood, treated, and prevented — for billions of people worldwide.
Read more about our ME genetics study
Read more about London Tech Week